Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Nathan, Paul, Hassel, Jessica C., Rutkowski, Piotr, Baurain, Jean-Francois, Butler, Marcus O., Schlaak, Max, Sullivan, Ryan J., Ochsenreither, Sebastian +20 more·2021·New England Journal of Medicine

DOI 10.1056/nejmoa2103485

Cited by (935)

Items 101–200 of 935

Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp
Jessica C. Hassel, Carola Berking, Andrea Forschner, Christoffer Gebhardt, Lucie Heinzerling, Friedegund Elke Meier, Sebastian Ochsenreither, Jens Thomas Siveke, Axel Hauschild, Dirk Schadendorf · 2023 · European Journal of Cancer
Long-term survival follow-up for tebentafusp in previously treated metastatic uveal melanoma
Joseph J. Sacco, Richard D. Carvajal, Marcus Otho Butler, Alexander Noor Shoushtari, Jessica C. Hassel, Alexandra P. Ikeguchi, Leonel Fernando Hernandez-Aya, Paul Nathan, Omid Hamid, Josep Maria Piulats et al. · 2024 · Journal for ImmunoTherapy of Cancer
Multipeptide vaccines for melanoma in the adjuvant setting: long-term survival outcomes and post-hoc analysis of a randomized phase II trial
Emily K. Ninmer, Hong Zhu, Kimberly A. Chianese‐Bullock, Margaret von Mehren, Naomi Balzer Haas, Merrick I. Ross, Lynn Thacher Dengel, Craig Lee Slingluff · 2024 · Nature Communications
Advances in targeted therapy and immunotherapy for melanoma (Review)
Ziyao Qin, Mei Zheng · 2023 · Experimental and Therapeutic Medicine
Combining Melphalan Percutaneous Hepatic Perfusion with Ipilimumab Plus Nivolumab in Advanced Uveal Melanoma: First Safety and Efficacy Data from the Phase Ib Part of the Chopin Trial
Thaïs M. L. Tong, Mark Christiaan Burgmans, Frank M. Speetjens, Arian R. van Erkel, Rutger W. van der Meer, Catherina S. P. van Rijswijk, M. A. Jonker-Bos, C. F. M. Roozen, M. Sporrel-Blokland, Jacob Lutjeboer et al. · 2023 · CardioVascular and Interventional Radiology
Tebentafusp in combination with durvalumab and/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study
Omid Hamid, Jessica C. Hassel, Alexander Noor Shoushtari, Friedegund Elke Meier, Todd Michael Bauer, April K.S. Salama, John M. Kirkwood, Paolo A. Ascierto, Paul C. Lorigan, Cornelia Mauch et al. · 2023 · Journal for ImmunoTherapy of Cancer
Advancements in γδT cell engineering: paving the way for enhanced cancer immunotherapy
Megan Yuan, Wenjun Wang, Isobel Hawes, Junwen Han, Zhenyu Yao, Alice Bertaina · 2024 · Frontiers in Immunology
Mechanism of Action and Pharmacokinetics of Approved Bispecific Antibodies
Seong‐Min Choi, Ju‐Hee Lee, Soyeon Ko, Soon‐Sun Hong, Hyo‐Eon Jin · 2024 · Biomolecules & Therapeutics
Targeting peptide antigens using a multiallelic MHC I-binding system
Haotian Du, Leena Mallik, Daniel H. Hwang, Yi Sun, Chengzi I. Kaku, Daniel Hoces, Shirley M. Sun, Reem Ghinnagow, Stephen D. Carro, Hoang Anh T. Phan et al. · 2024 · Nature Biotechnology
The future of targeted kinase inhibitors in melanoma
Signe Caksa, Usman Baqai, Andrew E. Aplin · 2022 · Pharmacology & Therapeutics
Is tebentafusp superior to combined immune checkpoint blockade and other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis with population adjustment.
A. Petzold, T. Steeb, A. Wessely, Elias A T Koch, Julio Vera, C. Berking, M. Heppt · 2023 · Cancer Treatment Reviews
T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors
Jim Middelburg, Marjolein Sluijter, Gaby Schaap, Büşra Göynük, Katy A. Lloyd, Vitalijs Ovcinnikovs, Gijs G. Zom, Renoud J. Marijnissen, Christianne Groeneveldt, Lisa Griffioen et al. · 2024 · Nature Communications
Engineering CD3/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer
Hirofumi Mikami, Shu Feng, Yutaka Matsuda, Shinya Ishii, Sotaro Naoi, Yumiko Azuma, Hiroaki Nagano, Kentaro Asanuma, Yoko Kayukawa, Toshiaki Tsunenari et al. · 2024 · Cancer Immunology Research
The Effectiveness of Cancer Immune Checkpoint Inhibitor Retreatment and Rechallenge—A Systematic Review
Adrian Perdyan, Bartosz Kamil Sobocki, Amar Balihodzic, Anna Dąbrowska, Justyna Kacperczyk, Jacek Rutkowski · 2023 · Cancers
Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting
Marco Ventin, Giulia Cattaneo, Shahrzad Arya, Jingyu Jia, Maria Chiara Gelmi, Yi Sun, Luke Maggs, Bruce R. Ksander, Robert M. Verdijk, Genevieve Marie Boland et al. · 2024 · Clinical Cancer Research
Gonadotoxicity of immunotherapy and targeted agents in patients with cancer and impact on subsequent pregnancies
Luca Arecco, Luciana de Moura Leite, Gabriella Gentile, Kristina Janković, Mihaela Stana, Silvia Ottonello, Graziana Scavone, Stefano Spinaci, Matteo Lambertini · 2025 · Human Reproduction
Percutaneous Hepatic Perfusion (PHP) with Melphalan in Liver-Dominant Metastatic Uveal Melanoma: The German Experience
Cornelia L. A. Dewald, Mia-Maria Warnke, Roland Brüning, Martin A. Schneider, Peter Wohlmuth, Jan Bernd Hinrichs, Anna Lena Saborowski, Arndt Vogel, Frank K. Wacker · 2021 · Cancers
A One-Armed Phase I Dose Escalation Trial Design: Personalized Vaccination with IKKβ-Matured, RNA-Loaded Dendritic Cells for Metastatic Uveal Melanoma
Elias A. T. Koch, Niels Schaft, Mirko Kummer, Carola Berking, Gerold Schuler, Kenichiro Hasumi, Jan Dörrie, Beatrice Schuler‐Thurner · 2022 · Frontiers in Immunology
Bispecific T-Cell Engagers and Chimeric Antigen Receptor T-Cell Therapies in Glioblastoma: An Update
Roa Alsajjan, Warren P. Mason · 2023 · Current Oncology
Prognostic and predictive biomarkers in melanoma
Nigel Gordon Maher, Ismael A. Vergara, Georgina Venetia Long, Richard A. Scolyer · 2023 · Pathology
A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma
Elizabeth Iannotti Buchbinder, Justine Vanessa Cohen, Giuseppe Tarantino, Christine Guo Lian, David Liu, Rizwan Haq, Frank Stephen Hodi, Donald P. Lawrence, Anita Giobbie‐Hurder, Deborah L. Knoerzer et al. · 2024 · Cancer Research Communications
Circulating Neoplastic-Immune Hybrid Cells Predict Metastatic Progression in Uveal Melanoma
Michael S. Parappilly, Yuki Chin, Riley M. Whalen, Ashley N. Anderson, Trinity L. Robinson, Luke Strgar, Thomas Lee Sutton, Patrick Conley, Christopher D. Klocke, Summer L. Gibbs et al. · 2022 · Cancers
Designing meaningful continuous representations of T cell receptor sequences with deep generative models
Allen Y. Leary, Darius Scott, Namita T. Gupta, Janelle C. Waite, Dimitris Skokos, Gurinder S. Atwal, Peter G. Hawkins · 2024 · Nature Communications
Mechanisms of antigen-dependent resistance to chimeric antigen receptor (CAR)-T cell therapies
Fatemeh Nasiri, Pouya Safarzadeh Kozani, Faeze Salem, Maral Mahboubi Kancha, Setareh Dashti Shokoohi, Pooria Safarzadeh Kozani · 2025 · Cancer Cell International
A Phase 1 study of ADI‐PEG20 (pegargiminase) combined with cisplatin and pemetrexed in ASS1‐negative metastatic uveal melanoma
Pui Ying Chan, Melissa M. Phillips, Stephen M. Ellis, Amanda L. Johnston, Xiaoxing Feng, Amit Arora, Gordon R. Hay, Victoria M.L. Cohen, Mandeep S. Sagoo, John S. Bomalaski et al. · 2022 · Pigment Cell & Melanoma Research
Multiorgan Involvement of Dormant Uveal Melanoma Micrometastases in Postmortem Tissue From Patients Without Coexisting Macrometastases
Viktor Gill, Emelie Norrman, Shiva Sabazade, Karim Ali, Emma Lardner, Gustav Stålhammar · 2023 · American Journal of Clinical Pathology
PRAME Expression: A Target for Cancer Immunotherapy and a Prognostic Factor in Uveal Melanoma
Maria Chiara Gelmi, Gülçin Gezgin, Pieter A. van der Velden, Gregorius P. M. Luyten, Sietse J. Luk, Mirjam H.M. Heemskerk, Martine Johanna Jager · 2023 · Investigative Ophthalmology & Visual Science
Recent Advances in Molecular and Genetic Research on Uveal Melanoma
Aurélie Fuentes-Rodriguez, Andrew Mitchell, Sylvain L. Guérin, Solange Landreville · 2024 · Cells
The current socioeconomic and regulatory landscape of immune effector cell therapies
Chiranjeevi Sainatham, Devvrat Yadav, Aravind Dilli Babu, Jayanth Reddy Tallapalli, Sai Gautham Kanagala, Evgenii Filippov, Franco Murillo-Chavez, Nausheen Ahmed, Forat Umair Lutfi · 2024 · Frontiers in Medicine
Bispecific immunotherapy based on antibodies, T-cell receptors, and aptamers: mechanisms of action, adverse effects, and future perspectives
Julia Lopatnikova, Sergey Vitalievich Sennikov · 2025 · Frontiers in Immunology
Conditionally active T cell engagers for the treatment of solid tumors: rationale and clinical development
Tseng-hui Timothy Chen · 2022 · Expert Opinion on Biological Therapy
Therapeutic antibodies for precise cancer immunotherapy: current and future perspectives
Longchao Liu, Jiahui Chen · 2022 · Medical Review
Revolutionizing cancer treatment: the power of bi- and tri-specific T-cell engagers in oncolytic virotherapy
Ali Zarezadeh Mehrabadi, Mahdi Tat, Akbar Ghorbani Alvanegh, Fatemeh Roozbahani, Hadi Esmaeili Gouvarchin Ghaleh · 2024 · Frontiers in Immunology
Cytokine release syndrome in solid tumors
David Synnott, David O’Reilly, D.G. de Freitas, Jarushka Naidoo · 2025 · Cancer
Targeting GNAQ/11 through PKC inhibition in uveal melanoma
Caressa Lietman, Meredith Ann McKean · 2022 · Cancer Gene Therapy
Genetic characterization of advanced conjunctival melanoma and response to systemic treatment
Georg Christian Lodde, Philipp Jansen, Inga Möller, Antje Sucker, Jessica C. Hassel, Andrea Forschner, Julia Eckardt, Friedegund Elke Meier, Lydia Reinhardt, Katharina Charlotte Kähler et al. · 2022 · European Journal of Cancer
Treatment with Anti-HER2 Chimeric Antigen Receptor Tumor-Infiltrating Lymphocytes (CAR-TILs) Is Safe and Associated with Antitumor Efficacy in Mice and Companion Dogs
Elin M.V. Forsberg, Rebecca E. Riise, Sara Saellström, Joakim W. Karlsson, Samuel Alsén, Valentina Bucher, Akseli Hemminki, Roger Olofsson Bagge, Lars Ny, Lisa M. Nilsson et al. · 2023 · Cancers
Mechanistically modeling peripheral cytokine dynamics following bispecific dosing in solid tumors
Jared C. Weddell · 2023 · CPT Pharmacometrics & Systems Pharmacology
The role of tumor-infiltrating lymphocytes in triple-negative breast cancer and the research progress of adoptive cell therapy
Ruonan Li, Lili Cao · 2023 · Frontiers in Immunology
Tebentafusp in Patients with Metastatic Uveal Melanoma: A Real-Life Retrospective Multicenter Study
Dirk Tomsitz, Theresa Ruf, Markus Vincent Heppt, Ramon Staeger, Egle Ramelyte, Reinhard Dummer, Marlene Garzarolli, Friedegund Elke Meier, Eileen Meier, Heike Richly et al. · 2023 · Cancers
Application of adoptive cell therapy in hepatocellular carcinoma
Dengqiang Wu, Yujie Li · 2023 · Immunology
Choroidal biopsies; a review and optimised approach
Rumana N. Hussain, Bertil E Damato, Heinrich Heimann · 2022 · Eye
T Cell–Redirecting Bispecific Antibodies in Multiple Myeloma: Optimal Dosing Schedule and Duration of Treatment
Niels W.C.J. van de Donk, Leo Rasche, Surbhi Sidana, Sonja Zweegman, Alfred L. Garfall · 2024 · Blood Cancer Discovery
Immune Effector Cell-associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
Jerry C. Lee, William Thomas Johnson, Melissa Hines, Nirali N. Shah · 2025 · Hematology/Oncology Clinics of North America
Advanced Acral Melanoma Therapies: Current Status and Future Directions
Yiqun Zhang, Shijie Lan, Di Wu · 2022 · Current Treatment Options in Oncology
High-throughput chemogenetic drug screening reveals PKC-RhoA/PKN as a targetable signaling vulnerability in GNAQ-driven uveal melanoma
Nadia Arang, Simone Lubrano, Michele Ceribelli, Damiano Cosimo Rigiracciolo, Robert Saddawi‐Konefka, Farhoud Faraji, Sydney I. Ramirez, Daehwan Kim, Frances Anne Tosto, Erica J. Stevenson et al. · 2023 · Cell Reports Medicine
A systematic review of antibody-drug conjugates and bispecific antibodies in head and neck squamous cell carcinoma and nasopharyngeal carcinoma: Charting the course of future therapies
Pablo Jiménez-Labaig, Antonio Rullan, Alberto Hernando‐Calvo, Sandra Llop, Shreerang A Bhide, Ben O’Leary, Irene Braña, Kevin Joseph Harrington · 2024 · Cancer Treatment Reviews
Uveal Melanoma Cell Line Proliferation Is Inhibited by Ricolinostat, a Histone Deacetylase Inhibitor
Husvinee Sundaramurthi, Sandra García‐Mulero, Valentina Tonelotto, Kayleigh Slater, Simone Marcone, Josep Maria Piulats, R. William G. Watson, Desmond John Tobin, Lasse D. Jensen, Breandán N. Kennedy · 2022 · Cancers
Potential of natural products and gut microbiome in tumor immunotherapy
Luchang Cao, Xinmiao Wang, Xinyi Ma, Manman Xu, Jie Li · 2024 · Chinese Medicine
Overcoming Resistance Mechanisms to Melanoma Immunotherapy
David X. Zheng, David J. Bozym, Giuseppe Tarantino, Ryan Joseph Sullivan, David Liu, Russell William Jenkins · 2024 · American Journal of Clinical Dermatology
T cell engagers emerge as a compelling therapeutic modality
Patrick A. Baeuerle, Karsten Sauer, Ricardo Grieshaber‐Bouyer, Jennifer S. Michaelson · 2025 · The Journal of Experimental Medicine
Is Tissue Still the Issue? The Promise of Liquid Biopsy in Uveal Melanoma
Daniël P. de Bruyn, Aaron B. Beasley, Robert M. Verdijk, Natasha M. van Poppelen, Dion A. Paridaens, Ronald O. B. de Keizer, Nicole C. Naus, Elin Solomonovna Gray, Annelies de Klein, Erwin Brosens et al. · 2022 · Biomedicines
Redirecting Polyclonal T Cells against Cancer with Soluble T-Cell Receptors
David M. Berman, John I. Bell · 2022 · Clinical Cancer Research
Chimeric Antigen Receptor T-Cell Therapy for Solid Tumors: The Past and the Future
Samer Ali Srour, Serkan Akın · 2022 · Journal of Immunotherapy and Precision Oncology
Nail Apparatus Melanoma: Current Management and Future Perspectives
Takamichi Ito, Hiroki Hashimoto, Yumiko Kaku‐Ito, Yuka Tanaka, Takeshi Nakahara · 2023 · Journal of Clinical Medicine
SAIL66, a next generation CLDN6-targeting T-cell engager, demonstrates potent antitumor efficacy through dual binding to CD3/CD137
Takayuki Kamikawa, Naoki Kimura, Shinya Ishii, Masaru Muraoka, Tatsushi Kodama, Kenji Taniguchi, Moe Yoshimoto, Momoko Okuda, Ryo Uchikawa, Chie Kato et al. · 2024 · Journal for ImmunoTherapy of Cancer
Targeting immunosenescence for improved tumor immunotherapy
Zaoqu Liu, Lulu Zuo, Zhaokai Zhou, Shutong Liu, Yuhao Ba, Anning Zuo, Yuqing Ren, Chuhan Zhang, Yukang Chen, Hongxuan Ma et al. · 2024 · MedComm
Combination of Immune Checkpoint Inhibitors and Liver-Specific Therapies in Liver-Metastatic Uveal Melanoma: Can We Thus Overcome Its High Resistance?
Chiara L. Blomen, Julian Kött, Tabea Isabelle Hartung, Leopold Konstantin Torster, Christoffer Gebhardt · 2021 · Cancers
Trends in Uveal Melanoma Presentation and Survival During Five Decades: A Nationwide Survey of 3898 Swedish Patients
Viktor Gill, Christina Herrspiegel, Shiva Sabazade, Maria Filì, Louise Bergman, Bertil E Damato, Stefan Seregard, Gustav Stålhammar · 2022 · Frontiers in Medicine
A three-arm randomised phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel in metastatic uveal melanoma
Joseph J. Sacco, Richard A. Jackson, Pippa G. Corrie, Sarah J. Danson, Thomas R. Jeffry Evans, Sebastian Ochsenreither, Satish Kumar, Andrew G. Goodman, James Larkin, Ioannis Karydis et al. · 2024 · European Journal of Cancer
Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease
Jason J. Luke, Diwakar Davar, Robert H.I. Andtbacka, Nina Bhardwaj, Joshua Brody, Jason Alan Chesney, Robert S. Coffin, Thierry de Baère, Tanja D. de Gruijl, Matthew G. Fury et al. · 2024 · Journal for ImmunoTherapy of Cancer
Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy
Amelia C. McCue, Stephen J. Demarest, Karen Froning, Michael J. Hickey, Stephen Antonysamy, Brian A. Kuhlman · 2024 · mAbs
Tebentafusp Induces a T-Cell–Driven Rash in Melanocyte-Bearing Skin as an Adverse Event Consistent with the Mechanism of Action
Jessica C. Hassel, Sarah Stanhope, Alexander Greenshields‐Watson, Devayani Machiraju, Alexander Heinrich Enk, Christopher Holland, Shaad Essa Abdullah, Adel Benlahrech, Marlana M. Orloff, Paul Nathan et al. · 2024 · Journal of Investigative Dermatology
Unlocking the potential of bispecific ADCs for targeted cancer therapy
Hongye Zeng, Wenjing Ning, Xue Liu, Wenxin Luo, Ningshao Xia · 2024 · Frontiers of Medicine
Focusing on CD8+ T-cell phenotypes: improving solid tumor therapy
Zhouchi Yao, Yayun Zeng, Cheng Liu, Huimin Jin, Hong Wang, Yue Zhang, Chengming Ding, Guodong Chen, Daichao Wu · 2024 · Journal of Experimental & Clinical Cancer Research
Tumor-Infiltrating Lymphocyte Therapy for the Treatment of Metastatic Melanoma
Katy K. Tsai, Krishna V. Komanduri · 2025 · American Journal of Clinical Dermatology
The Adrenergic Receptor Antagonist Carvedilol Elicits Anti-Tumor Responses in Uveal Melanoma 3D Tumor Spheroids and May Serve as Co-Adjuvant Therapy with Radiation
Lina S. Farhoumand, Miltiadis Fiorentzis, Miriam Monika Kraemer, Ali Sak, Martin Stuschke, Tienush Rassaf, Ulrike Barbara Hendgen-Cotta, Nikolaos Emmanouel Bechrakis, Utta Berchner‐Pfannschmidt · 2022 · Cancers
Phase 1b study of intravenous coxsackievirus A21 (V937) and ipilimumab for patients with metastatic uveal melanoma
Jose Lutzky, Ryan Joseph Sullivan, Justine Vanessa Cohen, Yixin Ren, Anlong Li, Rizwan Haq · 2023 · Journal of Cancer Research and Clinical Oncology
Tebentafusp in the Treatment of Metastatic Uveal Melanoma: Patient Selection and Special Considerations
Kamaneh Montazeri, Vikram Pattanayak, Ryan Joseph Sullivan · 2023 · Drug Design Development and Therapy
Magnetic Resonance Imaging in the Clinical Care for Uveal Melanoma Patients—A Systematic Review from an Ophthalmic Perspective
Myriam G. Jaarsma‐Coes, Lisa Klaassen, Marina Marinkovic, Gregorius P. M. Luyten, T. H. Khanh Vu, Teresa A. Ferreira, Jan‐Willem M. Beenakker · 2023 · Cancers
Iris melanoma: Review of clinical features, risks, management, and outcomes
Elliot G. Cherkas, Nicholas E. Kalafatis, Molly R. Marous, Carol L. Shields · 2023 · Clinics in Dermatology
Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors
Junjun Liu, Jianwei Zhu · 2024 · International Immunopharmacology
Discovery of Darovasertib (NVP-LXS196), a Pan-PKC Inhibitor for the Treatment of Metastatic Uveal Melanoma
Michael Visser, Julien P. N. Papillon, Michael J. Luzzio, Matthew J. LaMarche, Jianmei Fan, Walter Michael, David Wang, Alan Zhang, Christopher S. Straub, Simon Mathieu et al. · 2024 · Journal of Medicinal Chemistry
Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling
John Park, Ashleigh Stewart, Mal Irvine, Bernadette Pedersen, Zizhen Ming, Matteo Salvatore Carlino, Russell J. Diefenbach, Helen Rizos · 2022 · Cancer Gene Therapy
Recent advances and clinical pharmacology aspects of Chimeric Antigen Receptor (CAR) T‐cellular therapy development
Johannes Kast, Saeideh Nozohouri, Di Zhou, Marc R. Yago, Po‐Wei Chen, Malidi Ahamadi, Sandeep Dutta, Vijay V. Upreti · 2022 · Clinical and Translational Science
A Novel B7-H6–Targeted IgG-Like T Cell–Engaging Antibody for the Treatment of Gastrointestinal Tumors
Wei Zhang, Aurélie Auguste, Xiaoyun Liao, Christian Walterskirchen, K. H. Bauer, Yu-Hsi Lin, Ling Yang, Farzaneh H. Sayedian, Markus Fabits, Michael M. Bergmann et al. · 2022 · Clinical Cancer Research
Tebentafusp-tebn: A Novel Bispecific T-Cell Engager for Metastatic Uveal Melanoma
Gwen Hwa, PharmD, Daniel Carlson, DO, Jacqueline Rose Starr · 2022 · Journal of the Advanced Practitioner in Oncology
Efficacy of immune checkpoint inhibition in metastatic uveal melanoma: a systematic review and meta-analysis
James P. Pham, Lawrence On, Luke Ardolino, Joshua Hurwitz, Hélène Salaün, Hao‐Wen Sim, Anthony Michael Joshua · 2023 · Melanoma Research
Immunotherapy in Melanoma: Recent Advancements and Future Directions
Meghan J. Mooradian, Ryan Joseph Sullivan · 2023 · Cancers
Tuning the potency and selectivity of ImmTAC molecules by affinity modulation
Ian B. Robertson, Rachel Mulvaney, Nele M. G. Dieckmann, Alessio Vantellini, Martina Canestraro, Francesca Amicarella, Ronan O’Dwyer, David K. Cole, Stephen J Harper, Omer Dushek et al. · 2023 · Clinical & Experimental Immunology
Update on Thrombosis Risk in Patients with Cancer: Focus on Novel Anticancer Immunotherapies
Florian Moik, Jakob Michael Riedl, Cornelia Englisch, Cihan Ay · 2024 · Hämostaseologie
Single-cell RNA sequencing in melanoma: what have we learned so far?
Su Yin Lim, Helen Rizos · 2024 · EBioMedicine
Survival and Quality of Life After Isolated Hepatic Perfusion With Melphalan as a Treatment for Uveal Melanoma Liver Metastases
Roger Olofsson Bagge, Axel Nelson, Amir Shafazand, Charlotta All‐Eriksson, Christian Cahlin, Nils Elander, Anders Gustavsson, Hildur Helgadóttir, Jens Folke Kiilgaard, Sara Kinhult et al. · 2024 · Annals of Surgery
Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future
Lampe, Harriet, Tam, Laura, Hansen, Aaron R. · 2024 · Frontiers in Pharmacology
Cancer immunotherapy in elderly patients: The concept of immune senescence challenged by clinical experience
Mathilde Guégan, Malvina Bichon, Nathalie Chaput, Roch Houot, Jean Lemoine · 2024 · European Journal of Cancer
Enhancing immunotherapy efficacy with synergistic low-dose radiation in metastatic melanoma: current insights and prospects
Zahid Rafiq, Mingyo Kang, Hampartsoum B. Barsoumian, Gohar Shahwar Manzar, Yun Hang Hu, Carola Leuschner, Ailing Huang, Fatemeh Masrorpour, Weiqin Lu, Nahum Puebla‐Osorio et al. · 2025 · Journal of Experimental & Clinical Cancer Research
Pilot Trial of Arginine Deprivation Plus Nivolumab and Ipilimumab in Patients with Metastatic Uveal Melanoma
Lukas Kraehenbuehl, Aliya Holland, Emma Armstrong, Sirinya O’Shea, Levi Mark B Mangarin, Sara Chekalil, Amanda L. Johnston, John S. Bomalaski, Joseph Patrick Erinjeri, Christopher Andrew Barker et al. · 2022 · Cancers
A mAb against surface-expressed FSHR engineered to engage adaptive immunity for ovarian cancer immunotherapy
Devivasha Bordoloi, Pratik Sanjivkumar Bhojnagarwala, Alfredo Perales‐Puchalt, Abhijeet J. Kulkarni, Xizhou Zhu, Kevin Liaw, Ryan P. O’Connell, Daniel H. Park, Daniel W. Kulp, Rugang Zhang et al. · 2022 · JCI Insight
Globe Salvage and Vision Preservation by Neoadjuvant Darovasertib and Crizotinib in Uveal Melanoma
Alison Hiong, Roderick O’Day, Lotte Stubkjær Fog, D McKay, John D. McKenzie, Malaka Ameratunga, Anthony Michael Joshua, Mark J. Shackleton · 2023 · Ophthalmology Retina
Comprehensive causes of death in uveal melanoma: mortality in 1530 consecutively diagnosed patients followed until death
Gustav Stålhammar · 2023 · JNCI Cancer Spectrum
Management of Uveal Melanoma: Updated Cancer Care Alberta Clinical Practice Guideline
Ezekiel Weis, Brae Surgeoner, Thomas G. Salopek, Tina Cheng, Martin D. Hyrcza, Xanthoula Kostaras, Matthew P. Larocque, Greg McKinnon, John A. McWhae, Geetha Menon et al. · 2023 · Current Oncology
From Molecular Biology to Novel Immunotherapies and Nanomedicine in Uveal Melanoma
Kamil J. Synoradzki, Natalia Paduszyńska, Małgorzata Solnik, Mario Damiano Toro, Krzysztof Bilmin, Elżbieta Bylina, Piotr Lukasz Rutkowski, Yacoub Abdallah Yousef, Claudio Bucolo, Sandrine Anne Zweifel et al. · 2024 · Current Oncology
TAPIR: a T-cell receptor language model for predicting rare and novel targets
Ethan Fast, Manjima Dhar, Binbin Chen · 2023 · bioRxiv (Cold Spring Harbor Laboratory)
Incidence risk of peripheral edema in cancer patients treated with PD-1/PD-L1 inhibitors: A PRISMA guideline systematic review and meta-analysis
Yuan Tian, Alan Huang, Mei Tian, Kaiyong Wang, Qi Dang, Wei Zhang, Hongmei Liu, Junyan Zhao, Xiaowei Yang, Chi Zhang et al. · 2022 · Medicine
Induction of tertiary lymphoid structures in tumor microenvironment to improve anti-tumoral immune checkpoint blockade efficacy
Roman Vion, Matthieu Roulleaux Dugage, Ronan Flippot, Kaïssa Ouali, Mathieu Rouanne, Florian Clatot, MacLean Sellars, Stéphane Champiat, Nathalie Chaput, Christophe Massard et al. · 2025 · European Journal of Cancer
Potential Reasons for Unresponsiveness to Anti-PD1 Immunotherapy in Young Patients with Advanced Melanoma
Devayani Machiraju, Sarah Schäfer, Jessica C. Hassel · 2021 · Life
Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors
Kristen V. McClellan, Emerson Yu-sheng Chen, Adel Kardosh, Charles D. Lopez, Jaydira Del Rivero, Nadine Mallak, Flavio G. Rocha, Yilun Koethe, Rodney F. Pommier, Erik Mittra et al. · 2022 · Cancers
LKB1‐SIK2 loss drives uveal melanoma proliferation and hypersensitivity to SLC8A1 and ROS inhibition
Sarah Proteau, Imène Krossa, Chrystel Husser, Maxime Guéguinou, Federica Sella, Karine Bille, Marie Irondelle, Mélanie Dalmasso, Thibault Barouillet, Yann Chéli et al. · 2023 · EMBO Molecular Medicine
Prognostic Value of BAP1 Protein Expression in Uveal Melanoma
Susan Kennedy, Sally L. Owens, Laura P. Ivers, C. Hegarty, Valerie O’Neill, Jose Javier Berenguer-Pina, Noel Horgan, John Paul Crown, Naomi Walsh · 2024 · The American Journal of Surgical Pathology
The recent advancement of TCR-T cell therapies for cancer treatment
Xiang Zhao, Shuai Shao, Lanxin Hu · 2024 · Acta Biochimica et Biophysica Sinica